Embolic and Ablative Therapy for Hepatocellular Carcinoma.
| Autor: | Khalid M; Division of Gastroenterology, University of Maryland Medical Center, Baltimore, MD, USA., Likhitsup A; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA., Parikh ND; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. Electronic address: ndparikh@med.umich.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinics in liver disease [Clin Liver Dis] 2025 Feb; Vol. 29 (1), pp. 87-103. Date of Electronic Publication: 2024 Sep 11. |
| DOI: | 10.1016/j.cld.2024.08.003 |
| Abstrakt: | Embolic and ablative locoregional therapies (LRTs) for hepatocellular carcinoma are widely used to cure, bridge, or downstage patients for more definitive therapies. Common ablative therapies include microwave ablation and radiofrequency ablation, while embolic options include transarterial chemoembolization and 90Y transarterial radioembolization. While these therapies can be highly effective for the appropriate stage of disease, LRTs can suffer from a high rate of posttreatment recurrences. Considerations for administration of specific therapies include disease burden and underlying liver function. Recent data on concomitant or adjuvant systemic therapy, with LRT, have the potential to improve disease control and improve outcomes in this high-risk patient population. Competing Interests: Disclosure N.D. Parikh has provided consultation services for Exelixis and Exact Sciences and served on advisory boards for Genentech, Eisai, Gilead, Sirtex, Fujifilm Medical, and AstraZeneca. The other authors have no disclosures. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|